About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘faked data’ Category

Wrong in the tooth: Faked data, authorship issues force retraction of dental paper

leave a comment »

cridCase Reports in Dentistry has pulled a 2014 article about an oral parasitic infection (caution: not pretty) after learning that the authors were not exactly honest about their work.

Here’s the abstract of the paper, “Rhinosporidiosis of the Parotid Duct”: Read the rest of this entry »

About these ads

Written by Adam Marcus

September 12, 2014 at 10:30 am

Retraction appears for psychiatrist sought for arrest in alleged fraud scheme

with 6 comments

malafosse

Alain Malafosse, via University of Geneva

Want bogus data, million-dollar fraud allegations and a scientist on the lam? We give you Alain Malafosse.

The British Journal of Psychiatry has retracted a June 2013 paper by Malafosse and his colleagues on the genetics of bipolar disorder in children because Malafosse allegedly fabricated key data in the study.

The article, “Childhood maltreatment and methylation of the glucocorticoid receptor gene NR3C1 in bipolar disorder,” purported to find that people with bipolar disorder who had experienced more, and more severe, abuse early in life were more likely to show epigenetic changes. According to the abstract:

Read the rest of this entry »

Written by Adam Marcus

September 4, 2014 at 9:30 am

First author blamed for retraction in prestigious medical journal

with 40 comments

jemcoverThe authors of a Journal of Experimental Medicine have retracted it, blaming the first author for data and figure manipulation.

The paper, “The requirements for natural Th17 cell development are distinct from those of conventional Th17 cells,” was initially published in September 2011 and has been cited 25 times, according to Thomson Scientific’s Web of Knowledge. First author Jiyeon Kim was an MD-PhD candidate at the University of Pennsylvania until this year, according to a LinkedIn profile.

Here’s the notice: Read the rest of this entry »

Second retraction appears for former University of Florida ob-gyn subject to ORI probe

leave a comment »

University of Florida

Chegini, via University of Florida

Nasser Chegini, an ob-gyn formerly on the faculty at the University of Florida who has been the subject of an Office of Research Integrity (ORI) inquiry for several years, has a second retraction.

Chegini is suspected of having used bogus data in some of his work — research backed in part by some $4 million in federal funding.

The new retraction involves a 2008 paper in Reproductive Sciences on which Chegini was senior author. Here’s the notice: Read the rest of this entry »

Enthusiastic retraction and retracted correction mark loss of researcher’s fourth and fifth papers

with 2 comments

IJMPBHere’s a physics retraction whose use of an exclamation point — the only one we’ve ever seen in a retraction notice! — makes the editors’ exasperation palpable.

It’s also the the fourth retraction for R. K. Singhal, of the University of Rajasthan, Jaipur, India. Behold the notice for “Magnetic behavior of functionally modified spinel Ni0.4Ca0.6Fe2O4 nanoferrite,” in the International Journal of Modern Physics B: Read the rest of this entry »

A year after ORI report, hematology journal retracts faked paper

with 4 comments

bloodA year after an ORI report discredited the work of former University of Washington in Seattle researcher Andrew Aprikyan, one of the papers named in the report has finally been retracted.

Here’s the notice for “Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia”:  Read the rest of this entry »

Written by Cat Ferguson

August 6, 2014 at 9:30 am

MD Anderson postdoc faked results of Novartis anti-cancer compound study

with 35 comments

jun fu

Raymond Sawaya, director of MD Anderson’s brain tumor program, presents Jun Fu with the 2014 Caroline Ross Endowment Fellowship.

A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).

Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:

Read the rest of this entry »

Written by Ivan Oransky

August 1, 2014 at 8:00 am

Follow

Get every new post delivered to your Inbox.

Join 34,759 other followers